FDA Grants AP Status for Levocetirizine Dihydrochloride ANDA205564
The FDA has granted Abbreviated Approval (AP) status for ANDA205564, a generic formulation of Levocetirizine Dihydrochloride by Macleods Pharmaceuticals.
Asset / Drug
Drug and asset intelligence for Levocetirizine with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.